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Abstract
Background: Alterations in histone modifications are now well known to result in epigenetic heterogeneity in tumor
tissues; however, their prognostic value and association with resection margins still remain poorly understood and
controversial. Further, histopathologically negative resection margins in several cancers have been associated with
better prognosis of the disease. However, in gastric cancer, despite a high rate of R0 resection, a considerably high
incidence of loco-regional recurrence is observed. We believe alterations of global histone post-translational
modifications could help in identifying molecular signatures for defining the true negative surgical resection margins
and also the prognosis of gastric cancer patients.
Results: The present study compares the level of H3S10ph among paired tumor and histopathologically confirmed
disease-free (R0) proximal and distal surgical resection margin (PRM and DRM) tissue samples of GC patients (n= 101).
Immunoblotting and immune-histochemical analysis showed a significantly (p< 0.01) higher level of H3S10ph in tumor
compared to R0 surgical resection margins. Along with tumor, high H3S10ph levels in both PRM and DRM correlated
with clinical parameters and poor survival. Interestingly, in the case of PRM and DRM, the association of H3S10ph with
poor survival was only found in a patient group with the resection margin distance <4 cm. Further investigations
revealed that the increase of H3S10ph in tumor tissues is not due to the change in cell cycle profile but rather an
interphase-associated phenomenon. Moreover, an increase in ph-MSK1 and ph-p38 levels in tumor tissues and the
decrease in ph-MSK1 and H3S10ph on p38 inhibition in gastric cancer cells confirmed p38-MAPK/MSK1 pathway-
mediated regulation of H3S10ph in gastric cancer.
Conclusions: Our study provides the first evidence that p38-MAPK/MSK1-regulated increase of H3S10ph in GC is
predictive of a more aggressive cancer phenotype and could help in defining true negative surgical resection margin.
Importantly, our data also gave a new rationale for exploration of the use of MSK1 inhibitor in gastric cancer therapy and
the combination of histone post-translational modifications, H4K16ac and H4K20me3 along with H3S10ph as epigenetic
prognostic markers.
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Background
Gastric cancer (GC) is one of the most common malig-
nancies worldwide. Globally, GC ranks fourth and third
in terms of incidence and mortality, respectively [1]. In
India, it is one of the most aggressive cancers ranking
third and second in terms of incidence and mortality, re-
spectively [2]. Surgery remains the mainstay for cure es-
pecially in early cancers, while in locally advanced GC
the addition of perioperative/neoadjuvant chemotherapy
(NACT) affords a better survival advantage [3]. The
current standard practice in GC is to submit the
resected stomach for pathological examination to con-
firm the diagnosis and stage of the tumor as well as to
assess the margins of resection using hematoxylin and
eosin (H&E) staining. A pathologically negative resec-
tion/R0 margin affords the best chance of cure in GC
with 5-year survival rates of 13 versus 35 % for positive
and negative resection margins, respectively [4]. How-
ever, despite an apparently curative surgery, loco-
regional recurrence has still been encountered in 87 %
of GC patients [5]. Thus, raising the doubt on current
pathological techniques used in day to day practice to
truly confirm the adequacy of the R0 surgical resection
margins. Therefore, there is an urgent need to identify
molecular markers and investigate their expression in
not only the cancerous tissues but also the surrounding
resected (margin) tissue that is apparently free from dis-
ease (R0) based on histopathology.
Over the past decade, accumulated evidence indicates
towards the association of aberrant covalent histone
post-translational modifications (PTMs) with cancer
such as loss of acetylation of histone H4 at lysine 16
(H4K16ac) and tri-methylation of histone H4 at lysine
20 (H4K20me3), defined as “histone onco-modifications”
[6, 7]. In GC, a high level of tri-methylation of histone
H3 at lysine 9 (H3K9me3) was found to be correlated
with lympho-vascular invasion, recurrence, poor survival
rate, and as an independent prognostic marker [8]. In
addition to their role in disease prognosis, epigenetic al-
terations, specifically DNA methylation, are also re-
ported in field cancerization/defects in various types of
cancer, including stomach, liver, colon, lung, breast, kid-
ney, and esophageal [9]. However, the relation of histone
PTMs between tumor and resection margin and the
regulatory mechanism for their alteration is poorly
understood in cancer.
In this study on human GC, we identified phosphoryl-
ation of histone H3 at serine 10 (H3S10ph) as a histone
PTM with most consistent and significant difference be-
tween tumor and negative resection margin. For the first
time, our results demonstrate a distance-dependent (≤4
vs >4 cm) relation of H3S10ph of the tumor with both
PRM and DRM and also it correlates with the prognosis
of GC patients. Further, we report that phosphorylation
of H3S10 in GC is mediated by mitogen- and stress-
activated protein kinase-1 (MSK1) through the p38-
MAPK pathway.
Methods
Tissue samples and histopathological analysis
Frozen tissue sections (n = 36) and formalin-fixed
paraffin-embedded (FFPE) tissue blocks (n = 115) of the
tumor (T), PRM, and DRM from each gastric adenocar-
cinoma patients were obtained. All the patients were op-
erated between 2009 and 2012 at Tata Memorial
Hospital, Mumbai, India. Histopathological analysis in-
cluding determination of tumor content (% of tumor
cells) was done by a blinded gastrointestinal pathologist.
Based on the histopathological analysis, frozen tumor
tissues with ≥70 % tumor content, FFPE tumor tissues
with ≥10 % tumor content, and negative resection mar-
gins (without any tumor cell) were included in the study.
Finally, the study was conducted on paired tumor, PRM,
and DRM frozen tissues (n = 10), and FFPE tissue blocks
(n = 101). The protocol of the study was reviewed and
approved by the Institutional Review Board and Ethics
Committee (project number-466). All patients provided
a written informed consent.
Immunohistochemistry
Immunohistochemical (IHC) staining was performed
using VECTASTAIN® ABC kit (Vector Lab-P6200). FFPE
tissue blocks were sectioned at a thickness of 4 μm and
mounted on poly-L-lysine-coated glass slides. The sections
were deparaffinized through a graded series of xylene and
rehydrated through a graded series of absolute ethanol to
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distilled water. Endogenous peroxidase was quenched with
3 % hydrogen peroxide in methanol at room temperature
for 30 min in the dark. Microwave antigen retrieval was
carried out with 0.01 M Sodium citrate buffer (pH 6). Anti
H3S10ph (Abcam-1776), H3K16ac (Millipore-07-329),
H4K20me3 (Abcam-9053), and ph-MSK1 (Abcam-32190)
antibodies were applied for 16 h at 4 °C at the dilution of
1:100. Immunoreactive proteins were chromogenically de-
tected with diaminobenzidine (DAB; Sigma-D5537). The
sections were counterstained with Harris’s hematoxylin,
dehydrated, and mounted. In parallel, control staining was
performed without adding a primary antibody.
Evaluation of immunohistochemistry
The nuclear IHC staining for all the antibodies were
scored using H-score which is based on intensity of
staining (ranges from zero to three) and percentage of
stained cells using the following formula: H-score = [(0 ×
% of cells with staining intensity of zero) + (1 × % of cells
with staining intensity of one) + (2 × % of cells with
staining intensity one) + (3 × % of cells with staining in-
tensity two)]. H-score was further divided into three
groups: (i) 0–100: low level, (ii) 100–200: intermediate
level, and (iii) 200–300: high level. The IHC staining was
examined by two independent researchers (SAK and
MR), one of whom is a senior consultant pathologist
(MR). Both the researchers were blinded to all clinico-
pathological and outcome variables.
Cell culture, transfection, and treatment
GC cell lines, AGS (CRL-1739) and KATOIII (HTB-
103), were procured from ATCC. AGS and KATOIII
were cultured in RPMI1640 (Invitrogen) and F12K
(Himedia) media, respectively, at 37 °C with 5 % CO2
supplemented with 10 % FBS, 100 U/ml penicillin, and
100 mg/ml streptomycin (Sigma). AGS cells were trans-
fected using CaCl2 method with 10 μg of the pCMV-
flag-MSK1 construct. AGS and KATOIII cells were
treated for 1 h with chemical inhibitors against ph-p38
(SB203580, Calbiochem), ph-ERK (PD98059, Calbio-
chem), and ph-MSK1 (H89, Millipore) at 10 and 20 μM
concentrations for 1 h, respectively.
Total RNA isolation and RT-PCR
Total RNA was extracted (Thermo scientific-0731) from
25 mg of the frozen tumor and resection margin (PRM
or DRM) tissues with the maximum distance from the
site of the tumor. Total RNA (1 μg) was used for cDNA
synthesis (Fermentas-K1632) using random hexamers.
RT-PCR amplification was done using specific primers




CCATCCACA GAAA), cyclin-B1 (F:CGGGAAGTCAC
TGGAAACAT, R:CCGACCCAGACCAAAGTTTA),
cyclin-D1 (F:GATCAAGTGTGACCCGGACT, R:AGA-
GATGGAAGGGGGAAAGA), and 18S rRNA (F:AAA
CGGCTACCACATCCAAG, R:CCTCCAATGGATC
CTCGTTA) with an initial denaturation step at 95 °C
for 2 min, followed by 15 cycles of denaturation at 95 °C
for 45 s, primer annealing at 55 °C for 30 s, primer ex-
tension at 72 °C for 30 s, and a final extension at 72 °C
for 10 min. Amplified products were resolved on 1.5 %
agarose gels and visualized by EtBr staining.
Preparation of total cell lysate, nucleo-cytosolic fraction,
and histones
Cells were harvested from 90-mm plates and lysed in
200 μl of Laemmli buffer to prepare the total cell lysate
(TCL). Nucleo-cytosolic fraction (NCF) was prepared by
homogenizing 100 mg of frozen tissue in 2 ml of ice-
cold lysis buffer (20 mM Tris-Cl pH 8, 2 mM EDTA pH
8, 10 mM EGTA, 5 mM MgCl2, 0.1 % TritonX-100,
1 mM sodium orthovanadate, 1 mM sodium fluoride,
20 mM β-glycerophosphate, 1 mM DTT, 1 mM PMSF,
10 μg/ml leupeptin, 10 μg/ml aprotinin), and for cell
lines, 2 ml of ice-cold MKK lysis buffer (10 mM Tris-Cl,
1 mM EDTA, 1 mM EGTA, 1 % Triton X-100, 10 μg/ml
leupeptin, 10 μg/ml aprotinin, 1 mM PMSF, 1 mM so-
dium orthovanadate, 10 mM sodium fluoride, 10 mM β-
glycerophosphate) [10] was used for cells harvested from
a 90-mm plate. Both the homogenates were then kept at
4 °C for 30 min with intermittent mixing and then was
clarified by centrifugation at 16,000 rpm for 30 min. The
supernatant was collected as NCF and stored at −20 °C
until it is required, and the pellet was used for histone
isolation by acid extraction method [11]. For the prepar-
ation of NCF and histones, along with tumor, resection
margin (PRM or DRM) tissues with the maximum dis-
tance from the site of the tumor were used.
Electrophoresis and immunoblotting
TCL and NCF, and histones were resolved on 10 and 18 %
polyacrylamide SDS-PAGE, respectively, and transferred to
PVDF membrane. Proteins on PVDF membrane were hy-
bridized with anti-H3 (Upstate-06-755; 1:2000 dilution), H4
(Millipore-07-108; 1:4000 dilution), H3S10ph (Millipore-
06-570; 1:7000 dilution), H4K16ac (Millipore-07-329;
1:8000 dilution), H4K20me3 (Abcam-9053; 1:4000
dilution), β-actin (Sigma-A5316; 1:10,000 dilution), MSK1
(Santacruz-9392; 1:2000 dilution), ph-MSK1 (Abcam-
31190; 1:3000 dilution), ERK1/2 (Santacruz-292838; 1:2000
dilution), ph-ERK (Cell signaling-9910; 1:2000 dilution),
p38 (Santacruz-728; 1:2000 dilution), ph-p38 (Cell
signaling-9910; 1:2000 dilution), and anti-flag (Sigma-
F3165; 1:5000 dilution). Signal was visualized using horse-
radish peroxidase-conjugated anti-rabbit/mouse secondary
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antibody and ECL plus chemiluminescence kit (Amer-
sham). Wherever required, the densitometry analysis was
done on immunoblot and membrane to determine their
mean intensities using ImageJ software. For native proteins,
mean intensity of immunoblot was normalized with the
stained PVDF membrane; for phosphorylated forms, mean
intensity of immunoblot was normalized with immunoblot
of native proteins. The resulted value was used to express
their mean relative levels in resection margin and tumor.
Immunofluorescence microscopy
Cells grown on glass coverslips were fixed with 4 % parafor-
maldehyde for 20 min. Cells were then permeabilized in
PBS containing 0.5 % Triton X-100 for 20 min at RT and
then blocked with PBS containing 3 % BSA and 0.1 % NP-
40 for 1 h. Next, cells were incubated with a primary anti-
body against H3S10ph (Millipore-06-570) and ph-MSK1
(Abcam-31190) and appropriate secondary antibodies for
2 h each. Dilution of primary (1:100) and secondary anti-
bodies (Alexa-568 or Alexa-488; Cell signaling; 1:300 dilu-
tion) was made in blocking buffer. After the addition of
secondary antibody, all the steps were performed in the
dark and at room temperature. Finally, coverslips were
mounted in VECTASHIELD (Vector lab). Fluorescence in-
tensity was analyzed using a fluorescence microscope
(IX81; Olympus, Japan).
Cell cycle analysis
Frozen tissue (50 mg) was powdered using mortar and pes-
tle in liquid nitrogen. The powder was homogenized in
2 ml of nuclear buffer A (15 mM Tris-Cl pH 7.5, 60 mM
KCl, 15 mM NaCl, 2 mM EDTA, 0.5 mM EGTA, 0.34 M
sucrose, 0.15 mM β-ME, 0.15 mM spermine, and 0.5 mM
spermidine) using a Dounce homogenizer. In the case of
cell lines, cells were trypsinized and harvested in PBS.
Tissue homogenate and cells were then centrifuged
(5000 rpm for 15 min at 4 °C) to pellet nuclei and cells, re-
spectively; the supernatant was discarded. The pellet was
then fixed with 70 % chilled ethanol and stored at −20 °C.
When required, tissue nuclei/cells were washed with PBS
and suspended in 500 μl of PBS containing 0.1 % TritonX-
100 and 100 μg/ml of RNaseA and incubated at 37 °C for
30 min. After incubation, propidium iodide (25 μg/ml) was
added and nuclei were incubated at 37 °C for 30 min. DNA
content analysis was carried out in a FACSCalibur flow cyt-
ometer (BD Biosciences). Cell cycle analysis was performed
using the Mod-fit software.
Mitotic index analysis
Based on the morphology of nuclei, mitotic cells were
counted in 10 consecutive high power fields (HPF; ×40) of
H&E-stained tissue (tumor and resection margin) section
slides. Average of mitotic cells from 10 HPF was
represented as mitotic index. H&E staining was done as
per the standard protocol on 4-μm-thick FFPE tissue
sections.
Statistical analysis
To test the statistical significance of paired and unpaired
resection margin and tumor tissues, Wilcoxon matched
pair and Mann-Whitney test were used, respectively. To
test whether variables differed across groups, we used
the chi-square test. Chi-square analysis was used to find
the correlation between H3S10ph levels of the tumor,
PRM, and DRM tissues and clinical parameters. Survival
curves were plotted using the Kaplan-Meier method,
and the significance of the differences between the sur-
vival curves was determined using a univariate log-rank
test. To test the statistical independence and significance
of predictors, a multivariate survival analysis was per-
formed using the Cox proportional hazard regression
model. All p values were two-sided, and p < 0.05 was
considered significant. All statistical analyses were per-
formed with GraphPad and/or SPSS software.
Results
Level of H3S10ph in tumor and resection margin tissues
of GC
Histones were prepared from freshly resected paired (n
= 10) tumor and R0 resection margin (RM) tissues of
GC patients, for a pilot study. Histones and their re-
spective paraffin blocks were subjected to immunoblot-
ting and IHC analysis with site-specific acetylation,
methylation, and phosphorylation marks of histone H3
and H4 (data not shown). H3S10ph showed a most
consistent (9/10 patients) increase in tumor compared
to resection margin tissues in immunoblot analysis
(Fig. 1a). Further, the loss of H4K16ac and H4K20me3 is
a hallmark of the tumor [7]; however, it was not reported
in paired GC tissue samples. Our immunoblot and IHC
analysis in the paired tissues confirmed the decrease of
H4K16ac (8/10 patients) and H4K20me3 (8/10 patients)
in GC as well (Fig. 1a, b and Additional file 1: Figure S1).
The status of H3S10ph was further studied in a valid-
ation set (n = 101) among tumor and histopathologically
negative PRM and DRM tissues using IHC. IHC analysis
showed a high level of H3S10ph in tumor compared to
both the resection margins (Fig. 1c). H-score-based ana-
lysis of frequency distribution of tumor and PRM and
DRM tissue samples of GC patients showed 76, 57, and
42; 19, 40, and 44; and 6, 4, and 15 samples with a low,
intermediate and high level of H3S10ph, respectively
(Fig. 1d). Further, comparison of H-score showed a sig-
nificant high level of H3S10ph in tumor compared to
PRM (p < 0.001) and DRM (p < 0.001) tissues (Fig. 1e).
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Correlation of H3S10ph levels of tumor, PRM, and DRM
with clinicopathological variable of GC patients
Chi-square analysis was used to find a correlation be-
tween H3S10ph levels of the tumor, PRM, and DRM
tissues, and clinical parameters (Table 1). H3S10ph
levels of tumor tissues showed a significant positive
correlation with the World Health Organization
(WHO) classification (p = 0.0001), T stage (p = 0.005),
pTNM stage (p = 0.016), and recurrence (p = 0.034).
Interestingly, except recurrence, H3S10ph levels of
PRM and DRM tissues also showed a significant posi-
tive correlation with the same clinical parameters as
tumor tissues; WHO classification (p = 0.008 and
0.0001 for PRM and DRM, respectively), T stage (p =
0.001 and 0.003 for PRM and DRM, respectively), and
pTNM stage (p = 0.015 and 0.037 for PRM and DRM,
respectively). Only DRM showed a significant correl-
ation with recurrence (p = 0.012).
Correlation of H3S10ph levels of tumor and resection
margins with survival of GC patients
Overall survival (OS) and disease-free survival (DFS)
rate among groups with the low, intermediate, and
high level of H3S10ph was compared by log-rank
test/Kaplan-Meier survival analysis (Fig. 2). Analysis
showed a significant negative correlation of H3S10ph
Fig. 1 H3S10ph level in paired tumors and negative PRM and DRM GC tissue samples: a immunoblot analysis of H3S10ph, H4K16ac, and
H4K20me3 in freshly resected paired tumor and resection margin tissues (n = 10). b Representative image (left panel, ×40) and comparison of
mean H-score (right panel) for H4K16ac and H4K20me3 immunostaining (n = 10). c Representative images (×40) of H3S10ph immunostaining
(n = 101). d Comparison of frequency distribution with low (H-score 0–100), intermediate (H-score 100–200), and high (H-score 200–300) levels of
H3S10ph immunostaining (n = 101). e Comparative mean H-score of H3S10ph immunostaining (n = 101). GC gastric cancer, PRM proximal
resection margin, DRM distal resection margin, RM resection margin either PRM or DRM with maximum distance from the site of the tumor,
P patient. Statistical tests are done by using Wilcoxon matched pairs test. *p < 0.05, **p < 0.01, ***p<0.001
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levels of tumor (p = 0.004 and 0.011), PRM (p = 0.014
and 0.004), and DRM (p = 0.026 and 0.006) with OS
and DFS, respectively (Fig. 1a–c). Moreover, H3S10ph
levels of the tumor, but not the PRM and DRM, were
found to be independent predictors of overall survival
(Additional file 2: Table S1). Therefore, together, data
of this and previous sections confirm the association
of a high level of H3S10ph of resection margins along
with tumor tissues with poor prognosis of GC.
Relation of H3S10ph levels of resection margins and their
distance from the site of the tumor in GC
Our observation of the low level of H3S10ph in resection
margin compared to tumor tissues led us to examine
whether the decrease had any relation with the distance of
resection margin from the site of the tumor. To answer
this, we first grouped the resection margin samples as per
their distance from the tumor site and compared the mean
H-score of H3S10ph immunostaining of each group with
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≤50 15 (35.7) 18 (40.9) 6 (40.0) 0.879‡ 31 (40.8) 6 (31.6) 2 (33.3) 0.734‡ 21 (36.8) 16 (40.0) 2 (50.0) 0.849‡
>50 27 (64.3) 26 (59.1) 9 (60.0) 45 (59.2) 13 (68.4) 4 (66.7) 36 (63.2) 24 (60.0) 2 (50.0)
Sex
Male 29 (69.0) 32 (72.7) 9 (60.0) 0.652‡ 53 (69.7) 11 (57.9) 6 (100.0) 0.148‡ 40 (70.2) 26 (65.0) 4 (100.0) 0.343‡
Female 13 (31.0) 12 (27.7) 6 (40.0) 23 (30.3) 8 (42.1) 0 (0.0) 17 (29.8) 14 (35.0) 0 (0.0)
WHO classification
WD 2 (4.8) 0 (0.0) 0 (0.0) 0.0001‡ 2 (2.6) 0 (0.0) 0 (0.0) 0.008‡ 2 (3.5) 0 (0.0) 0 (0.0) 0.0001‡
MD 22 (52.4) 3 (6.8) 0 (0.0) 24 (31.6) 1 (5.3) 0 (0.0) 23 (40.4) 2 (5.0) 0 (0.0
PD 16 (38.1) 40 (40.9) 7 (46.7) 44 (57.9) 16 (84.2) 3 (50.0) 29 (50.9) 33 (82.5) 1 (25.0)
SRC 2 (4.8) 1 (2.3) 8 (53.3) 6 (7.9) 2 (10.5) 3 (50.0) 3 (5.3) 5 (12.5) 3 (75.0)
T stage
T1 9 (21.4) 4 (9.1) 1 (6.7) 0.005† 13 (17.1) 1 (5.3) 0 (0.0) 0.001† 11 (19.3) 3 (7.5) 0 (0.0) 0.003†
T2 11 (26.2) 10 (22.7) 3 (20.0) 22 (28.9) 2 (10.5) 0 (0.0) 14 (24.6) 10 (25.0) 0 (0.0
T3 16 (38.1) 20 (45.5) 2 (13.3) 26 (34.2) 10 (52.6) 2 (33.3) 23 (40.4) 15 (37.5) 0 (0.0)
T4 6 (14.3) 10 (22.7) 9 (60.0) 15 (19.7) 6 (31.6) 4 (66.7) 9 (15.8) 12 (30.0) 4 (0.0)
Lymph node metastasis
Absent 20 (47.6) 27 (61.4) 10 (66.7) 0.136† 42 (55.3) 10 (52.6) 5 (83.3) 0.385† 30 (52.6) 24 (60.0) 3 (75.0) 0.311†
Present 22 (52.4) 17 (38.6) 5 (33.3) 34 (44.7) 9 (47.4) 1 (16.7) 27 (47.4) 16 (40.0) 1 (25.0)
pTNM stage
I 14 (33.3) 7 (15.9) 1 (6.7) 0.016† 20 (26.3) 2 (10.5) 0 (0.0) 0.015† 17 (29.8) 5 (12.5) 0 (0.0) 0.037†
II 15 (35.7) 22 (50.0) 6 (40.0) 33 (43.4) 8 (42.1) 2 (33.3) 22 (38.6) 20 (50.0) 1 (25.0)
III 13 (31.0) 14 (31.8) 7 (46.7) 22 (28.9) 8 (42.1) 4 (66.7) 17 (29.8) 14 (35.0) 3 (75.0)
IV 0 (0.0) 1 (2.3) 1 (6.7) 1 (1.3) 1 (5.3) 0 (0.0) 1 (1.8) 1 (2.5) 0 (0.0)
Recurrence
Absent 32 (76.2) 28 (63.6) 7 (46.7) 0.034† 54 (71.1) 8 (42.1) 5 (83.3) 0.351† 43 (75.4) 23 (57.5) 1 (25.0) 0.012†
Present 10 (23.8) 16 (36.4) 8 (53.3) 22 (28.9) 11 (57.9) 1 (16.7) 14 (24.6) 17 (42.5) 3 (75.0)
Treatment modality
Surgery 24 (57.1) 21 (47.7) 12 (80.0) 0.093‡ 43 (56.6) 11 (57.9) 3 (50.0) 0.943‡ 28 (49.1) 26 (65.0) 3 (75.0) 0.087‡
NACT +
Surgery
18 (42.9) 23 (52.3) 3 (20.0) 33 (43.4) 8 (42.1) 3 (50.0) 29 (50.9) 14 (35.0) 1 (25.0)
All three columns are compared in each category: †chi-square test by two-sided linear-by-linear association; ‡chi-square test by two-sided Fisher’s exact test. Italics
indicates values that are statistically significant (<0.05)
Int. intermediate, PRM proximal resection margin, DRM distal resection margin
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Fig. 2 (See legend on next page.)
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the mean H-score of tumor samples (Fig. 3). For both
PRM and DRM, a significant reduction in HS10ph (p
< 0.05) was observed for patient’s group with resec-
tion margin distance >4 cm (Fig. 3a, b, left panel).
Further, patients were divided into two groups based
on the distance of resection margin ≤4 or >4 cm and their
mean H-scores were compared with the tumor tissues.
Interestingly, further analysis showed H3S10ph levels of
resection margins with the distance ≤4 cm were almost
equal to those of the tumor tissues; however, resection
margins with >4 cm showed a significant (p < 0.001)
reduction in both PRM and DRM (Fig. 3a, b, middle
panel). Additionally, immunoblot analysis also con-
firmed the reduction of H3S10ph levels of resection
margins if the distance is >4 cm from the site of the
tumor (Fig. 3a, b, right panel).
(See figure on previous page.)
Fig. 2 Effect of H3S10ph levels of tumor, PRM, and DRM on GC patients’ survival. Kaplan-Meier survival analysis was done according to H3S10ph
staining H-score: low (0–100), intermediate (100–200), and high (200–300). High level of H3S10P of tumor and PRM and DRM is associated with
both poor overall survival (OS) and disease-free survival (DFS). a OS and DFS based on H3S10P levels of tumor tissues, b OS and DFS based on
H3S10P levels of PRM tissues, c OS and DFS based on H3S10P levels of DRM tissues. GC gastric cancer, PRM proximal resection margin, DRM distal
resection margin, Int. intermediate. Comparison was done by log-rank test. p < 0.05 was considered as significant
Fig. 3 Association of H3S10ph with the distance of negative resection margins in GC. a, c Resection margins were grouped as per their distance from
the site of the tumor with 1 cm interval and mean H-score of H3S10ph immunostaining of each group was compared with tumor (left panel). In case
of both PRM and DRM, analysis showed a significant decrease in H3S10ph levels as the margin length reaches more than 4 cm (left panel). Comparison
of mean H-score of H3S10ph immunostaining of all resection margins with a margin distance ≤4 and >4 cm with tumor confirms the significant
reduction of H3S10ph if the margin distance is >4 cm (right panel). b, d Confirmation of reduction of H3S10ph, if the margin length is >4 cm by
immunoblotting. GC gastric cancer, PRM proximal resection margin, DRM distal resection margin. Statistical tests are done by using Mann-Whitney test
(†) and Wilcoxon matched pairs test. *p < 0.05, **p < 0.01, ***p<0.001
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Effect of resection margin distance on prognostic value of
H3S10ph in GC
To investigate the effect of resection margin distance
from the site of the tumor on the prognostic value of
H3S10ph, its association with clinicopathological vari-
ables and survival was compared between the group
with the resection margin ≤4 and >4 cm. Chi-square
analysis (Table 2) showed a positive correlation of
Table 2 Correlation between H3S10ph levels of PRM and DRM, ≤4 vs >4 cm
Total (n = 101) H3S10 phosphorylation level of PRM ≤4 cm (n = 48) p value H3S10 phosphorylation level of PRM >4 cm (n = 53) p value
Low (%), n = 28 Int. (%), n = 14 High (%), n = 6 Low (%), n = 48 Int. (%), n = 5 High (%), n = 0
WHO classification
WD 1 (3.6) 0 (0.0) 0 (0.0) 0.001‡ 1 (2.1) 0 (0.0) 0 (0.0) 0.632‡
MD 14 (50.0) 1 (7.1) 0 (0.0) 10 (20.8) 0 (0.0) 0 (0.0)
PD 12 (42.9) 12 (85.7) 3 (50.0) 32 (66.7) 4 (80.0) 0 (0.0)
SRC 1 (3.6) 1 (7.1) 3 (50.0) 5 (10.4) 1 (20.0) 0 (0.0)
T stage
T1 6 (21.4) 1 (7.1) 0 (0.0) 0.002† 7 (14.6) 0 (0.0) 0 (0.0) 0.121†
T2 10 (35.7) 2 (14.3) 0 (0.0) 12 (25.0) 0 (0.0) 0 (0.0)
T3 8 (28.6) 7 (50.0) 2 (33.3) 18 (37.5) 3 (60.0) 0 (0.0)
T4 4 (14.3) 4 (28.6) 4 (66.7) 11 (22.9) 2 (40.0) 0 (0.0)
pTNM stage
I 10 (35.7) 2 (14.) 0 (0.0) 0.023† 10 (20.8) 0 (0.0) 0 (0.0) 0.068†
II 10 (35.7) 6 (42.9) 2 (33.3) 23 (47.9) 2 (40.0) 0 (0.0)
III 8 (28.6) 6 (42.9) 4 (66.7) 14 (29.2) 2 (40.0) 0 (0.0)
IV 0 (0.0) 0 (0.0 0 (0.0) 1 (2.1) 1 (10.0) 0 (0.0)
Recurrence
Absent 20 (71.4) 8 (57.1) 5 (57.1) 0.956† 34 (70.8) 2 (40.0) 0 (0.0) 0.193†
Present 8 (28.6) 6 (42.9) 1 (16.7) 14 (29.2) 3 (50.0) 0 (0.0)
Total (n = 101) H3S10 phosphorylation level of DRM ≤4 cm (n = 62) p value H3S10 phosphorylation level of DRM >4 cm (n = 39) p value
Low (%), n = 24 Int. (%), n = 34 High (%), n = 4 Low (%), n = 33 Int. (%), n = 6 High (%), n = 0
WHO classification
WD 1 (4.2) 0 (0.0) 0 (0.0) 0.0001‡ 1 (3.0) 0 (0.0) 0 (0.0) 0.6‡
MD 10 (41.7) 1 (2.9) 0 (0.0) 13 (39.4) 1 (16.7) 0 (0.0)
PD 12 (4.2) 29 (85.3) 1 (25.0) 17 (51.5) 4 (66.7) 0 (0.0)
SRC 1 (4.2) 4 (11.8) 3 (75.0) 2 (6.1) 1 (16.7) 0 (0.0)
T stage
T1 5 (20.8) 3 (8.8) 0 (0.0) 0.009 6 (18.2) 0 (0.0) 0 (0.0) 0.287†
T2 6 (25.0) 8 (23.5) 1 (25.0) 8 (24.2) 2 (33.3) 0 (0.0)
T3 9 (37.5) 13 (38.2) 3 (75.0) 14 (42.4) 2 (33.3) 0 (0.0)
T4 4 (16.7) 10 (29.4) 0 (0.0) 5 (15.2) 2 (33.3) 0 (0.0)
pTNM stage
I 5 (20.8) 5 (14.7) 0 (0.0 0.361† 12 (36.4) 0 (0.0) 0 (0.0) 0.107†
II 9 (37.5) 17 (50.0) 1 (25.0) 13 (39.4) 3 (50.0) 0 (0.0)
III 10 (41.7) 11 (32.4) 3 (75.0) 7 (21.2) 3 (50.0) 0 (0.0)
IV 0 (0.0) 1 (2.9) 0 (0.0) 1 (3.0) 0 (0.0) 0 (0.0)
Recurrence
Absent 19 (79.2) 13 (38.2) 1 (25.0) 0.031† 24 (72.7) 4 (66.7) 0 (0.0) 0.063†
Present 5 (20.8) 21 (61.8) 3 (75.0) 9 (27.3) 2 (33.3) 0 (0.0)
All three columns are compared in each category: †chi-square test by two-sided linear-by-linear association; ‡chi-square test by two-sided Fisher’s exact test. Italics
indicates values that are statistically significant (<0.05)
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H3S10ph levels with WHO classification (p = 0.001), T
stage (p = 0.002), and TNM stage (p = 0.023) for the pa-
tients with resection margin ≤4 cm. In case of DRM,
chi-square analysis showed a positive correlation of
H3S10ph levels with WHO classification (p = 0.0001)
and T stage (p = 0.009) and recurrence (p = 0.031) for
the patients with resection margins ≤4 cm. For both the
resection margins, no correlation was found for patients
with >4 cm resection margin distance.
In the case of OS, patients with PRM ≤4 cm showed a
significant (p = 0.003) difference among the group of
high, intermediate, and low levels of H3S10ph
(Additional file 3: Figure S2A) and no difference was ob-
served in the case of DRM (Additional file 2: Figure
S1C). However, in the case of DFS, distance seems to
have no effect as patients with both ≤4 or >4 cm resec-
tion showed significant difference in survival among the
group of high, intermediate, and low levels of H3S10ph
for both PRM (p = 0.028 vs 0.006) and DRM (p = 0.041
vs 0.005). Moreover, when the patients were grouped
just based on the distance of the resection margin from
the site of the tumor (≤4 or >4 cm), no significant differ-
ence was observed in the case of both OS and DFS
(Additional file 4: Figure S3).
Taken together, these data indicate that the distance of
resection margin is an important factor in GC prognosis
and H3S10ph could be a potential biomarker in predict-
ing the association between distance of resection margin
and clinical parameters. However, H3S10ph cannot be
used to predict the survival difference based on the dis-
tance of the resection margin for both PRM and DRM.
Association of an increase of H3S10ph with the phase of
cell cycle in GC
H3S10ph is a very dynamic histone mark and its level
changes throughout the cell cycle with the highest level
in mitotic phase and the lowest level in the interphase of
the cell cycle [12, 13]. Therefore, to determine whether
the increase of H3S10ph in GC is dependent on the cell
cycle profile of the tissues samples, cyclin levels, mitotic
index, and cell cycle profile of the tumor and resection
margin tissues were studied (Fig. 4). Cyclin B1, D1, and
E1 levels are known to peak at the time of G2/M phase
transition, mid-S phase, and G1/S phase transition, re-
spectively. RT-PCR analysis showed the increase in the
messenger RNA (mRNA) levels of all the cyclins in
tumor than the resection margin tissues; however, no
changes were observed in their ratios between the tumor
and resection margin tissues (Fig. 4a). The mitotic index
also did not show any significant increase in mitotic cells
in tumor compared to resection margin tissues (Fig. 4b).
Flow cytometry-based cell cycle analysis of tissue sam-
ples showed an equal percentage of G1, S, and G2/M
cells in the tumor and resection margin tissues with a
maximum population of cells in the G1 phase (Fig. 4c).
These results indicate that the observed increase of
H3S10ph in GC is not because of the enrichment of cells
in any cell cycle phase in tumor compared to resection
margin tissues.
In the mitotic phase, H3S10ph is associated with chro-
matin condensation and transcription silencing while in
the interphase of cell cycle an increase of H3S10ph is as-
sociated with chromatin relaxation and transcription up-
regulation of mainly immediate early (IE) genes [12, 13].
Cell cycle analysis revealed about 80 % cells of the tumor
and resection margin tissues were in G1 phase (Fig. 4c).
Therefore, to determine whether the increase in H3S10ph
in GC is an interphase-associated phenomenon or not, we
checked the levels of IE genes (c-jun and c-fos) using RT-
PCR and immunoblotting. The data showed an increase
in the levels of c-jun and c-fos in tumor compared to re-
section margin tissues (Fig. 4d). Therefore, taken together,
these data confirm that increase in H3S10ph levels in GC
is not due to the alteration in the cell cycle phase, but an
interphase-associated phenomenon.
MSK1 phosphorylates H3S10 through p38-MAPK pathway
in GC
Several kinases are known to phosphorylate H3S10 [12];
however, only mitogen- and stress-activated protein kinase-
1 (MSK1)-mediated phosphorylation of H3S10 is known to
be involved in cellular transformation [11] which is acti-
vated through p38 and/or ERK1/2 MAP kinase pathway
[14]. In addition, overexpression of c-jun and c-fos as
observed in our experiments (Fig. 4d) has also been linked
to MSK1-mediated phosphorylation of H3S10 at their pro-
moters [15]. Therefore, ph-MSK1, ph-p38, and ph-ERK1/2
levels in tumor and resection margin tissues of GC patients
were analyzed. Immunoblot (Fig. 5a, upper panel) as well as
its densitometry analysis (Fig. 5a, lower panel) showed the
significant increase of ph-MSK1 (p < 0.001), p38 (p < 0.01),
and ph-p38 (p < 0.001), while ph-ERK1/2 (p < 0.001) levels
significantly decrease in tumor compared to resection
margin tissues, thus, indicating p38-mediated activation of
MSK1 in GC. The increase of ph-MSK1 levels in GC was
further confirmed by IHC analysis of the same tissues
(Fig. 5b). The observed increase of H3S10ph on the overex-
pression of MSK1 in AGS cells by immunoblot (Fig. 5c and
Additional file 5: Figure S4A) and, moreover, decrease of
H3S10ph- on H89-mediated biochemical inhibition of
MSK1 by immunoblot studies in AGS and KATOII cell
lines (Fig. 5d and Additional file 5: Figure S4B) and
immunofluorescence studies in AGS cells (Fig. 5e) con-
firmed MSK1-mediated phosphorylation of H3S10 in GC.
Further, immunoblot analysis with specific antibodies
showed a decrease of ph-MSK1 and H3S10ph only on the
treatment of p38 inhibitor (SB203580) in AGS and
KATOIII cells but not on the treatment of ERK1/2
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inhibitor (PD89059) (Fig. 5f). And immunofluorescence
studies on inhibitor-treated AGS cells validated that p38 is
responsible for phosphorylation of MSK1 in GC (Fig. 5g),
thus, confirming p38-MAPK/MSK1-mediated increase of
H3S10ph in GC.
Discussion
In this study on human GC, comparison of several histone
PTMs (data not shown) between the tumor and R0 resec-
tion margin tissues using immunoblot and IHC resulted
H3S10ph with most consistent and significant difference
(Fig. 1a, b and Additional file 2: Figure S1). Therefore,
H3S10ph was taken for detailed study. To the best of our
knowledge, several cell line- and animal model-based
studies have shown increase in H3S10ph, as the only
histone mark involved in carcinogenesis and cellular
transformation [11, 16–18]. However, there is no report
on its relative level (tumor vs resection margin) and regu-
latory pathway in GC. Our IHC analysis in paired samples
(n = 101), for the first time, demonstrated an increase of
H3S10ph in gastric tumor compared to both negative re-
section margins, PRM and DRM (Fig. 1c–e). This obser-
vation also corroborated earlier study in nasopharyngeal
carcinoma (NPC) where H3S10ph was found to be signifi-
cantly higher in the poorly differentiated NPC tissues than
normal nasopharynx tissues [17]. On further analysis with
clinical parameters, we identified that an increase of
H3S10ph in tumor tissues is a marker of poor prognosis
and independent prognostic marker for OS in GC (Table 1,
Additional file 1: Table S1 and Fig. 2a).
Fig. 4 Association of cell cycle profile with GC tumor and resection margin tissues. a RT-PCR analysis shows a high mRNA level of cyclin B1, D1, and E1
in tumor than resection margin tissues (left panel). mRNA level of cyclins were normalized with 18S rRNA, combined % was calculated for each cyclin
in tumor and resection margin tissues, and their relative % levels were compared showing no difference in cell cycle profile of tumor and resection
margin tissues (right panel). b Arrow heads showing mitotic cells in H&E-stained resection margin and tumor tissue section image (×40, left panel). On
H&E-stained tissue sections, mitotic index was calculated for paired samples (n = 40), comparison between tumor and resection margin tissues showing
no significant difference (right panel). c Flow cytometry-based cell cycle profile showed most of the cells of both tumor and resection margin tissues
are in G1 phase (upper panel). Comparison of mean % (n = 10) of G2/M, G1, and S phases of cell cycle showed no difference in cell cycle profile of
tumor and resection margin tissues (lower panel). d RT-PCR (left upper panel) and immunoblot (left lower panel) analyses showed a high level of
immediate early genes, c-jun and c-fos, in tumor than resection margin tissues. After normalization, comparison of relative level also showed significant
increase of c-jun and c-fos in tumor tissues, both at transcript (right upper panel) and protein (right lower panel) level. GC gastric cancer, RM resection
margin either PRM or DRM with maximum distance from the site of the tumor, T tumor, P patient. #Fast green-stained PVDF membrane used in
Fig. 5a as well. Statistical tests are done by using Wilcoxon matched pairs test. *p < 0.05, **p < 0.01, ***p<0.001
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Fig. 5 (See legend on next page.)
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Currently, surgery is the main treatment modality for
GC and achieving adequate margin length for R0 resec-
tion is a major challenge. With 9–21 % false negative re-
sults, palpation, gross inspection, and even assessment
of tumor and resection margin by frozen section exam-
ination are seemingly unreliable methods to judge the
adequacy of resection [19, 20]. Studies in esophageal,
pancreatic, rectal, and oral cancer and soft tissue sar-
coma have demonstrated that a negative resection mar-
gin does not have any prognostic value; however, a
positive resection margin and its length affect recurrence
and survival of patients [21–25]. The alarmingly high
loco-regional recurrence rate in GC patients with R0 re-
section [26] points towards the fact that a defined nega-
tive resection margin is not a “true” negative resection
margin. In our study, H3S10ph of both PRM and DRM
showed association with clinical parameters and poorly
affects OS and DFS (Table 1; Fig. 2b, c). Additionally,
H3S10ph levels of DRM showed a positive correlation
with recurrence where disease reverted back in 75 % pa-
tients in the high-level H3S10ph group compared to
42.5 and 24.6 % in the intermediate and low level
H3S10ph groups, respectively. Thus, this study for the
first time identified H3S10ph as a potential molecular
marker for predicting prognosis of R0 resected GC pa-
tients using their histopathologically confirmed negative
resection margins. Further, distance-dependent associ-
ation of H3S10ph with clinical parameters (Table 2)
could be utilized in determining the “true” negative re-
section margin in GC. Demarcation of 4 cm as an opti-
mal margin length in our study rationalizes the
recommendations of the National Comprehensive Can-
cer Network at the molecular level, which state that “the
resection margin of more than 4 cm is necessary to
achieve a negative microscopic margin” [27]. Therefore,
H3S10ph could be helpful in limiting the extent of re-
section and thereby preventing post-surgery loco-
regional recurrence of disease.
The distance-dependent relation of H3S10ph with
clinical parameters (Table 2) strongly suggests its associ-
ation with field cancerization defects. Moreover, various
epigenetic factors like chromatin state, histone deacety-
lase, microRNA, DNA methylation, and chromatin
remodeling factors have shown their involvement in field
cancerization in a number of cancers including GC [28–
31]. Further, earlier in vitro studies have shown that a
higher level of H3S10ph alone is directly involved in cel-
lular transformation [11]. Therefore, the occurrence of
such epigenetic field defects may facilitate a more per-
missive chromatin environment for the growth of newly
transformed cells. Hence, analysis of high H3S10ph
levels in resection margins could predispose the tissue
for a high rate GC recurrence after R0 resection.
Most of the earlier reports have shown H3S10ph as a
better marker for assessing proliferation and mitotic
index than Ki-67 and have also shown increase of
H3S10ph as a marker for poor prognosis in several can-
cers including GC [32–37]. However, except glioblast-
oma study, none of the cancer studies have used paired
normal mucosa or negative resection margin along with
tumor tissues; therefore, it is difficult to comment on
whether the high proliferation and/or mitotic index or
G2/M phase cells is the reason for the increased level of
H3S10ph in cancer. H3S10ph is known to regulate
protein-protein interactions to favor chromatin conden-
sation as cells enter the M phase, whereas it favors ex-
pression of immediate early genes in G1 phase of cell
cycle. In light of these cell cycle-specific functions, our
data (Fig. 4a–c) have shown no difference in the relative
level of cyclins, mitotic index, and cell cycle profile be-
tween tumor and paired negative resection margin tis-
sues, thus strongly suggesting that an increase of
H3S10ph is independent of G2/M cell cycle phase in
GC. A recent report has also shown a cell cycle-
independent cigarette side-stream smoke-induced in-
crease of H3S10ph leading to the overexpression of
proto-oncogenes, c-jun and c-fos, and tumor promotion
[18]. Further, our study also showed the presence of
maximum percentage of cells in the G1 phase of the cell
cycle (Fig. 4c), and overexpression of c-jun and c-fos in
tumor compared to paired negative resection margin tis-
sues lead us to believe that the increase of H3S10ph is
associated with G1 phase-specific alterations in GC.
Interestingly, global H3S10ph modification levels were
lower in “true” negative resection margin tissue and in-
creased significantly in GC. This indicates that the
(See figure on previous page.)
Fig. 5 Regulatory mechanism for differential levels of H3S10ph in GC. a Immunoblot analysis (upper panel) of paired tissue (n = 5) and densitometry-
based analysis of relative levels (lower panel) showed a significant increase in ph-MSK1 and ph-p38 levels and decrease in ph-ERK1/2 levels in tumor
compared to resection margin tissues. b Representative image of immunohistochemistry (×40) (left panel) analysis in paired tissue samples (n = 10) and
comparison of their relative H-score (right panel) showed high ph-MSK1 levels in tumor than resection margin tissues. c Immunoblot analysis of AGS
cells transiently over-expressing MSK1 showed moderate increase of ph-MSK1 and H3S10ph in corresponding lanes. d, e Immunoblot analysis of AGS
and KATOII cells and immunofluorescence analysis of AGS cells after 6-h treatment with MSK1 inhibitor, H89 (20 μM) showed loss of ph-MSK1 and
H3S10ph. f, g Immunoblot analysis of AGS and KATOII cells and immunofluorescence analysis of AGS cells showed loss of ph-MSK1 and H3S10ph only
after 1-h treatment of p38 inhibitor SB203580 (10 μM), but not for ERK1/2 inhibitor PD98059 (10 μM) treatment. GC gastric cancer, RM resection margin
either PRM or DRM with maximum distance from the site of the tumor, T tumor, P patient. #Fast green-stained PVDF membrane used in Fig. 4d as well.
Statistical tests are done by using Wilcoxon matched pairs test. *p < 0.05, **p < 0.01, ***p<0.001
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action of the histone-modifying enzymes differs in the
resection margin as compared to GC tissues. In our
study, a G1 phase-associated increase of H3S10ph and
high expression of IE genes, c-jun and c-fos (Fig. 4), sug-
gest that G1-specific kinase and MSK1 may be phos-
phorylating H3S10 [12]. Moreover, MSK1 is the only
known kinase of H3S10 whose direct role has been im-
plicated in cellular transformation [11, 38]. This notion
was further strengthened by the observed high level of
ph-MSK1 (an active form of MSK1) in GC tumor tissues
(Fig. 5a, b). MSK1 is phosphorylated by MAP kinases,
ERK1/2, or p38 in a context-dependent manner [14, 39].
In GC, ph-ERK1/2 has been reported to have no associ-
ation with clinical parameters [40]. On the other hand,
several studies in different cancer like prostate, breast,
bladder, liver, lung, transformed follicular lymphoma,
and leukemia have suggested a direct role of p38 MAPK
in cancer patho-physiological characteristics like prolif-
eration, metastasis, and angiogenesis [41–47]. Further,
p38 MAPK being a key regulator of inflammatory re-
sponse and chronic inflammation is a characteristic of
GC which manifests itself by overexpression of pro-
inflammatory cytokines like IL-1 and IL-6 [48–50].
Therefore, along with above stated facts, our findings
conclude that p38-MAPK/MSK1, but not ERK1/2-
MAPK/MSK1, pathway is regulating the H3S10ph in
GC (Fig. 5).
Conclusions
In summary, to the best of our knowledge, this study pro-
vides the first evidence of a p38-MAPK/MSK1 pathway-
regulated increase in H3S10ph with a strong prognostic
Fig. 6 Schematic representation showing p38-MAPK/MSK1 governing upregulation of H3S10ph and MSK1 as a potential target in gastric cancer
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value in survival as well as in defining the “true” resection
margin in GC (Fig. 6). The central role of MSK1-mediated
nucleosomal response via H3S10ph in GC might be asso-
ciated with the induction of aberrant gene expression. Fur-
ther, the coherence of H3S10ph in GC with two well-
known reported altered histone modifications in human
cancers, H4K16ac and H3K20me3, suggests that combin-
ation of epigenetic modifications may serve as molecular
biomarkers for GC. Importantly, our data gave new ratio-
nales for using MSK1 as a molecular target along with
other epi-drugs to alter the epigenetic landscape in GC for
better patient care.
Additional files
Additional file 1: Figure S1. Densitometry analysis of immunoblot of
Figure 1a. Immunoblot was done for indicated antibodies using histone
isolated from tumor (T) and negative resection margin (RM) of gastric
cancer patients (n = 10). Mean intensities of H4K20me3 and H4K16ac
were normalized with mean intensity of H4; similarly H3S10ph with H3.
Normalized values were represented as relative levels in the form of bar
graphs. Statistical tests are done by using Wilcoxon matched pairs test.
*p<0.05, **p<0.01, ***p<0.001. (JPG 64 kb)
Additional file 2: Table S1. Survival analysis of variables predicting the
risk of death for patients with gastric cancer. (DOCX 30 kb)
Additional file 3: Figure S2. Effect of distance of resection margin-
dependent H3S10ph levels on GC patients’ survival. Kaplan-Meier survival
analysis was done according to H3S10ph staining H-score; low (0–100),
intermediate (100–200), and high (200–300). (A) and (B) Low level of
H3S10ph associates with better overall survival (OS) of the patients with
PRM ≤4 cm; however it does not affect disease-free survival (DFS). (C) and
(D) Low level of H3S10ph associates with better OS and DFS, however,
distance does not affect this association. GC-gastric cancer; PRM-proximal
resection margin; DRM-distal resection margin; Int. - Intermediate. Compari-
son was done by log-rank test. p < 0.05 was considered as significant.
(TIF 1036 kb)
Additional file 4: Figure S3. Effect of 4 cm resection margin distance on
GC patients’ survival. Kaplan-Meier survival analysis according to H3S10ph
staining H-score: low (0–100), intermediate (100–200), and high (200–300).
High level of H3S10P of tumor, PRM, and DRM is associated with both poor
overall survival (OS) and disease-free survival (DFS). (A) OS and DFS based on
H3S10P levels of tumor tissues (B) OS and DFS based on H3S10P levels of
PRM tissues (C) OS and DFS based on H3S10P levels of DRM tissues. Int. -
Intermediate. Comparison was done by log-rank test. p < 0.05 was consid-
ered as significant. (TIF 649 kb)
Additional file 5: Figure S4. Cell cycle analysis of AGS cells. Flow
cytometry-based cell cycle profile after transfection (A) and H89 treatment
(B) showed identical cell cycle profile with negligible apoptosis or cell death.
(TIF 311 kb)
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